Artal Group S.A. Black Diamond Therapeutics, Inc. Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$2.67 - $5.74 $2.67 Million - $5.74 Million	-1,000,000 Reduced 48.86%	1,046,517 $5.31 Million
Q2 2023 Aug 11, 2023	BUY	$1.43 - $6.18 $572,000 - $2.47 Million	400,000 Added 24.29%	2,046,517 $10.3 Million
Q4 2020 Feb 11, 2021	BUY	$29.47 - $35.0 $3.68 Million - $4.38 Million	125,000 Added 8.22%	1,646,517 $52.8 Million
Q3 2020 Nov 13, 2020	SELL	$26.17 - $43.07 $654,250 - $1.08 Million	-25,000 Reduced 1.62%	1,521,517 $46 Million
Q2 2020 Aug 14, 2020	SELL	$22.3 - $44.8 $3.35 Million - $6.72 Million	-150,000 Reduced 8.84%	1,546,517 $65.2 Million
Q1 2020 May 14, 2020	BUY	$18.18 - $39.48 $30.8 Million - $67 Million	1,696,517 New	1,696,517 $42.3 Million

117

48.8M

1.84M

1.93M

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $80.7M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.